http://www.pathologyjournal.rcpa.edu.au/article/S0031-3025(15)00041-0/abstract
immunotherapy for cancer: progress at a cost we can afford?
Ian H. Frazer
The University of Queensland School of Medicine, Translational Research Institute, Brisbane, Qld, Australia
DOI: http://dx.doi.org/10.1016/j.pathol.2015.12.014
Article Infoclick to expand contents
Tumours express, as ‘non-self’ proteins, mutated self proteins, viral gene products, and oncofetal antigens. These proteins often induce non-protective host immune responses, demonstrable as circulating antibody. There should therefore be the possibility of inducing host protective immune response through immunisation against these proteins, although to date this has not proven a successful strategy for treatment of human tumours. Recent advances in understanding of the physiological regulation of immune responses has led to development of a number of non-antigen specific regulators of host immunity, termed checkpoint blockade inhibitors. Administration of these biologics, by inhibiting mechanisms designed to curtail immune responses no longer required, can result in immune mediated control and in some cases resolution of solid organ tumours including squamous lung and kidney cancers, and melanoma. Research is currently focused on defining biomarkers that will predict, or indicate, responsiveness to treatment.
- Forums
- ASX - By Stock
- AVR
- cardiocel paper
cardiocel paper, page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.14 |
Change
0.000(0.00%) |
Mkt cap ! $277.7M |
Open | High | Low | Value | Volume |
$13.33 | $13.91 | $13.14 | $302.2K | 22.46K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 299 | $13.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.49 | 35 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 299 | 13.140 |
4 | 2791 | 13.000 |
2 | 67 | 12.900 |
1 | 1000 | 12.500 |
1 | 10000 | 12.000 |
Price($) | Vol. | No. |
---|---|---|
13.490 | 35 | 1 |
13.500 | 750 | 1 |
13.880 | 200 | 1 |
14.000 | 3000 | 1 |
14.100 | 100 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online